Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...

在癌症治疗中，抗氧化剂像一把“双刃剑”：试图保护健康细胞的同时，却可能为癌细胞撑起保护伞。冷泉港团队在研究中发现维生素K前体MSB的促氧化特性竟能精准瓦解前列腺癌的生存防线，并同时展现出改善遗传性肌病小鼠表型的潜力。“坏事变好事”的背后是一种全新细胞 ...

研究发现，胃腺体是单克隆细胞群体的单位，每年大约积累28个体细胞单核苷酸变异（SNV），主要归因于内源性突变过程。在胃癌患者中，化生腺体由于与增殖和氧化损伤相关的突变过程加速，往往表现出较高的突变负担。研究还发现，胃上皮细胞通常携带特定染色体的重复三 ...

NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored ...

Cancer epigenetics is the study of somatically heritable changes to molecular processes that influence the flow of information between the DNA of cancer cells and their gene expression patterns ...

这篇综述系统阐述了早发性子宫内膜癌（EOEC）发病率上升的严峻趋势，强调遗传（如PTEN突变）、环境（肥胖）及表观遗传 ...

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...